From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against Cancer

PLoS Pathogens

Volumn 10, Issue 1, 2014, Pages

  Ilkow, Carolina S ^a   Swift, Stephanie L ^b   Bell, John C ^a,c   Diallo, Jean Simon ^a,c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b Swift Science Writing   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL; GENETICS; HUMAN; METABOLISM; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PROCEDURES;

ANIMALS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84893715844     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003836     Document Type: Review

References (131)

1. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
2. Russell SJ, Peng KW, Bell JC, (2012) Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
3. Mendelsohn CL, Wimmer E, Racaniello VR, (1989) Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56: 855-865.
4. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, et al. (2009) Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 183: 4921-4930.
5. Enloe BM, Jay DG, (2011) Inhibition of Necl-5 (CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2 expression and activity. J Neurooncol 102: 225-235.
6. Masson D, Jarry A, Baury B, Blanchardie P, Laboisse C, et al. (2001) Overexpression of the CD155 gene in human colorectal carcinoma. Gut 49: 236-240.
7. Nakai R, Maniwa Y, Tanaka Y, Nishio W, Yoshimura M, et al. (2010) Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci 101: 1326-1330.
8. Suzuki K, Nakamura K, Kato K, Hamada H, Tsukamoto T, (2007) Exploration of target molecules for prostate cancer gene therapy. Prostate 67: 1163-1173.
9. Goetz C, Dobrikova E, Shveygert M, Dobrikov M, Gromeier M, (2011) Oncolytic poliovirus against malignant glioma. Future Virol 6: 1045-1058.
10. Gaggar A, Shayakhmetov DM, Lieber A, (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9: 1408-1412.
11. Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G, et al. (2003) Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 77: 9183-9191.
12. Anderson BD, Nakamura T, Russell SJ, Peng KW, (2004) High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 64: 4919-4926.
13. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, et al. (2011) Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480: 530-533.
14. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, et al. (2010) Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 134: 835-845.
15. Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, et al. (2005) Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 280: 19543-19550.
16. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, et al. (2009) Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 69: 6694-6703.
17. Skelding KA, Barry RD, Shafren DR, (2009) Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21. Breast Cancer Res Treat 113: 21-30.
18. Giaginis CT, Zarros AC, Papaefthymiou MA, Papadopouli AE, Sfiniadakis IK, et al. (2008) Coxsackievirus and adenovirus receptor expression in human endometrial adenocarcinoma: possible clinical implications. World J Surg Oncol 6: 59.
19. Shafren DR, Williams DT, Barry RD, (1997) A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J Virol 71: 9844-9848.
20. Wang KS, Kuhn RJ, Strauss EG, Ou S, Strauss JH, (1992) High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 66: 4992-5001.
21. Basolo F, Pollina L, Pacini F, Fontanini G, Menard S, et al. (1996) Expression of the Mr 67,000 laminin receptor is an adverse prognostic indicator in human thyroid cancer: an immunohistochemical study. Clin Cancer Res 2: 1777-1780.
22. Castronovo V, Colin C, Claysmith AP, Chen PH, Lifrange E, et al. (1990) Immunodetection of the metastasis-associated laminin receptor in human breast cancer cells obtained by fine-needle aspiration biopsy. Am J Pathol 137: 1373-1381.
23. Cioce V, Castronovo V, Shmookler BM, Garbisa S, Grigioni WF, et al. (1991) Increased expression of the laminin receptor in human colon cancer. J Natl Cancer Inst 83: 29-36.
24. Menard S, Tagliabue E, Colnaghi MI, (1998) The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat 52: 137-145.
25. Jamieson KV, Hubbard SR, Meruelo D, (2011) Structure-guided identification of a laminin binding site on the laminin receptor precursor. J Mol Biol 405: 24-32.
26. Verheije MH, Rottier PJ, (2012) Retargeting of viruses to generate oncolytic agents. Adv Virol 2012: 798526.
27. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, et al. (2005) Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209-214.
28. Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, et al. (2007) Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther 15: 677-686.
29. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Johnston PB, et al. (2007) Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 67: 10939-10947.
30. Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, et al. (2006) The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 12: 6170-6178.
31. Coughlan L, Vallath S, Saha A, Flak M, McNeish IA, et al. (2009) In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol 83: 6416-6428.
32. Gupta V, Wang W, Sosnowski BA, Hofman FM, Chen TC, (2006) Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells. Neurosurg Focus 20: E26.
33. Harvey TJ, Burdon D, Steele L, Ingram N, Hall GD, et al. (2010) Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. Gene Ther 17: 1000-1010.
34. Oh IK, Mok H, Park TG, (2006) Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. Bioconjug Chem 17: 721-727.
35. Wang W, Zhu NL, Chua J, Swenson S, Costa FK, et al. (2005) Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy. J Neurosurg 103: 1058-1066.
36. Galmiche MC, Rindisbacher L, Wels W, Wittek R, Buchegger F, (1997) Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting. J Gen Virol 78 (Pt 11) (): 3019-3027.
37. Paul S, Geist M, Dott K, Snary D, Taylor-Papadimitriou J, et al. (2007) Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles. Viral Immunol 20: 664-671.
38. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
39. Indraccolo S, (2010) Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity 43: 244-247.
40. Kotredes KP, Gamero AM, (2013) Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res 33: 162-170.
41. Subramaniam PS, Johnson HM, (1997) A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons. J Interferon Cytokine Res 17: 11-15.
42. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, et al. (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17: 2619-2627.
43. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, et al. (2005) A critical function for type I interferons in cancer immunoediting. Nat Immunol 6: 722-729.
44. Fiola C, Peeters B, Fournier P, Arnold A, Bucur M, et al. (2006) Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer 119: 328-338.
45. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A, (2006) Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80: 5145-5155.
46. Shmulevitz M, Pan LZ, Garant K, Pan D, Lee PW, (2010) Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res 70: 4912-4921.
47. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, et al. (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
48. Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW, et al. (2012) Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26: 1870-1878.
49. Noll M, Berchtold S, Lampe J, Malek NP, Bitzer M, et al. (2013) Primary resistance phenomena to oncolytic measles vaccine viruses. Int J Oncol 43: 103-112.
50. Haralambieva I, Iankov I, Hasegawa K, Harvey M, Russell SJ, et al. (2007) Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther 15: 588-597.
51. Le Boeuf F, Batenchuk C, Vaha-Koskela M, Breton S, Roy D, et al. (2013) Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat Commun 4: 1974.
52. Brun J, McManus D, Lefebvre C, Hu K, Falls T, et al. (2010) Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther 18: 1440-1449.
53. Le Boeuf F, Diallo J-S, McCart JA, Thorne S, Falls T, et al. (2010) Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18: 888-895.
54. Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, et al. (2012) The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J Virol 86: 4566-4577.
55. Bridle BW, Chen L, Lemay CG, Diallo J-S, Pol J, et al. (2013) HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 21: 887-894.
56. MacTavish H, Diallo J-S, Huang B, Stanford M, Le Boeuf F, et al. (2010) Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS ONE 5: e14462 doi:10.1371/journal.pone.0014462.
57. Chang HM, Paulson M, Holko M, Rice CM, Williams BR, et al. (2004) Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A 101: 9578-9583.
58. Nguyen TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, et al. (2008) Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A 105: 14981-14986.
59. Diallo J-S, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, et al. (2010) A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther 18: 1123-1129.
60. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
61. Abrahams MR, Zhang Z, Chien S, Skerns T, Kotwal GJ, (2005) The vaccinia virus N1L ORF may encode a multifunctional protein possibly targeting different kinases, one of which influences ATP levels in vivo. Ann N Y Acad Sci 1056: 87-99.
62. Gammon DB, Gowrishankar B, Duraffour S, Andrei G, Upton C, et al. (2010) Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis. PLoS Pathog 6: e1000984 doi:10.1371/journal.ppat.1000984.
63. Elford HL, Freese M, Passamani E, Morris HP, (1970) Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem 245: 5228-5233.
64. Chung RY, Saeki Y, Chiocca EA, (1999) B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 73: 7556-7564.
65. Aghi M, Visted T, Depinho RA, Chiocca EA, (2008) Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 27: 4249-4254.
66. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, et al. (2006) Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14: 361-370.
67. Liu BL, Robinson M, Han ZQ, Branston RH, English C, et al. (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10: 292-303.
68. Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, et al. (2010) Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res 70: 3890-3895.
69. Ruggero D, (2013) Translational control in cancer etiology. Cold Spring Harb Perspect Biol 5: a012336.
70. Bjornsti MA, Houghton PJ, (2004) Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 5: 519-523.
71. Holland EC, Sonenberg N, Pandolfi PP, Thomas G, (2004) Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23: 3138-3144.
72. Barber GN, (2005) VSV-tumor selective replication and protein translation. Oncogene 24: 7710-7719.
73. Stanford MM, McFadden G, (2007) Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther 7: 1415-1425.
74. Garcia MA, Meurs EF, Esteban M, (2007) The dsRNA protein kinase PKR: virus and cell control. Biochimie 89: 799-811.
75. Kawagishi-Kobayashi M, Silverman JB, Ung TL, Dever TE, (1997) Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate inhibitor K3L is dependent on residues conserved between the K3L protein and the PKR substrate eIF2alpha. Mol Cell Biol 17: 4146-4158.
76. Balachandran S, Barber GN, (2004) Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5: 51-65.
77. Richter JD, Sonenberg N, (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433: 477-480.
78. Chuluunbaatar U, Roller R, Feldman ME, Brown S, Shokat KM, et al. (2010) Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication. Genes Dev 24: 2627-2639.
79. Sabatini DM, (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734.
80. Liu TC, Wakimoto H, Martuza RL, Rabkin SD, (2007) Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin Cancer Res 13: 5897-5902.
81. Alain T, Lun X, Martineau Y, Sean P, Pulendran B, et al. (2010) Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A 107: 1576-1581.
82. Colina R, Costa-Mattioli M, Dowling RJ, Jaramillo M, Tai LH, et al. (2008) Translational control of the innate immune response through IRF-7. Nature 452: 323-328.
83. Costa-Mattioli M, Sonenberg N, (2008) RAPping production of type I interferon in pDCs through mTOR. Nat Immunol 9: 1097-1099.
84. Oliere S, Arguello M, Mesplede T, Tumilasci V, Nakhaei P, et al. (2008) Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 82: 5735-5749.
85. Correa RJ, Komar M, Tong JG, Sivapragasam M, Rahman MM, et al. (2012) Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Gynecol Oncol 125: 441-450.
86. Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, et al. (2010) Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res 70: 598-608.
87. Stanford MM, Shaban M, Barrett JW, Werden SJ, Gilbert PA, et al. (2008) Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 16: 52-59.
88. Fu X, Tao L, Rivera A, Zhang X, (2011) Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication. Int J Cancer 129: 1503-1510.
89. Homicsko K, Lukashev A, Iggo RD, (2005) RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 65: 6882-6890.
90. Lun XQ, Jang JH, Tang N, Deng H, Head R, et al. (2009) Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 15: 2777-2788.
91. Brass N, Heckel D, Sahin U, Pfreundschuh M, Sybrecht GW, et al. (1997) Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet 6: 33-39.
92. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, et al. (2007) A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 28: 501-512.
93. Goetz C, Gromeier M, (2010) Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev 21: 197-203.
94. Fitzgerald KD, Semler BL, (2011) Re-localization of cellular protein SRp20 during poliovirus infection: bridging a viral IRES to the host cell translation apparatus. PLoS Pathog 7: e1002127 doi:10.1371/journal.ppat.1002127.
95. Kastan MB, Bartek J, (2004) Cell-cycle checkpoints and cancer. Nature 432: 316-323.
96. Ben-Israel H, Kleinberger T, (2002) Adenovirus and cell cycle control. Front Biosci 7: d1369-1395.
97. Crescenzi M, Soddu S, Tato F, (1995) Mitotic cycle reactivation in terminally differentiated cells by adenovirus infection. J Cell Physiol 162: 26-35.
98. Poggioli GJ, DeBiasi RL, Bickel R, Jotte R, Spalding A, et al. (2002) Reovirus-induced alterations in gene expression related to cell cycle regulation. J Virol 76: 2585-2594.
99. Yoo NK, Pyo CW, Kim Y, Ahn BY, Choi SY, (2008) Vaccinia virus-mediated cell cycle alteration involves inactivation of tumour suppressors associated with Brf1 and TBP. Cell Microbiol 10: 583-592.
100. Bandara LR, La Thangue NB, (1991) Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Nature 351: 494-497.
101. Zamanian M, La Thangue NB, (1992) Adenovirus E1a prevents the retinoblastoma gene product from repressing the activity of a cellular transcription factor. EMBO J 11: 2603-2610.
102. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, et al. (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2-12.
103. Kim M, Williamson CT, Prudhomme J, Bebb DG, Riabowol K, et al. (2010) The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 29: 3990-3996.
104. Martin S, Harris DT, Shisler J, (2012) The C11R gene, which encodes the vaccinia virus growth factor, is partially responsible for MVA-induced NF-kappaB and ERK2 activation. J Virol 86: 9629-9639.
105. Tao Y, Song X, Deng X, Xie D, Lee LM, et al. (2005) Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp Cell Res 303: 240-251.
106. Twardzik DR, Brown JP, Ranchalis JE, Todaro GJ, Moss B, (1985) Vaccinia virus-infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors. Proc Natl Acad Sci U S A 82: 5300-5304.
107. Holbro T, Civenni G, Hynes NE, (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284: 99-110.
108. Esfandiarei M, Luo H, Yanagawa B, Suarez A, Dabiri D, et al. (2004) Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol 78: 4289-4298.
109. Hsu MJ, Wu CY, Chiang HH, Lai YL, Hung SL, (2010) PI3K/Akt signaling mediated apoptosis blockage and viral gene expression in oral epithelial cells during herpes simplex virus infection. Virus Res 153: 36-43.
110. Soares JA, Leite FG, Andrade LG, Torres AA, De Sousa LP, et al. (2009) Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication. J Virol 83: 6883-6899.
111. Werden SJ, Lanchbury J, Shattuck D, Neff C, Dufford M, et al. (2009) The myxoma virus m-t5 ankyrin repeat host range protein is a novel adaptor that coordinately links the cellular signaling pathways mediated by Akt and Skp1 in virus-infected cells. J Virol 83: 12068-12083.
112. Sypula J, Wang F, Ma Y, Bell J, McFadden G, (2004) Myxoma virus tropism in human tumor cells. Gene Ther Mol Biol 8: 103-114.
113. Fu X, Tao L, Cai R, Prigge J, Zhang X, (2006) A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther 13: 882-890.
114. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW, (2007) Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 15: 1522-1530.
115. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW, (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362.
116. Endo T, Toda M, Watanabe M, Iizuka Y, Kubota T, et al. (2002) In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther 9: 142-148.
117. Melcher A, Parato K, Rooney CM, Bell JC, (2009) Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19: 1008-1016.
118. Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, et al. (2009) Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381.
119. Vigil A, Martinez O, Chua MA, Garcia-Sastre A, (2008) Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther 16: 1883-1890.
120. Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, et al. (2005) The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 65: 9991-9998.
121. Vijayalingam S, Subramanian T, Ryerse J, Varvares M, Chinnadurai G, (2009) Down-regulation of multiple cell survival proteins in head and neck cancer cells by an apoptogenic mutant of adenovirus type 5. Virology 392: 62-72.
122. Jin J, Liu H, Yang C, Li G, Liu X, et al. (2009) Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Mol Cancer Ther 8: 1387-1397.
123. Sathaiah M, Thirunavukkarasu P, O'Malley ME, Kavanagh MA, Ravindranathan R, et al. (2012) Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer. Cancer Gene Ther 19: 192-201.
124. Chalikonda S, Kivlen MH, O'Malley ME, Eric Dong XD, McCart JA, et al. (2008) Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther 15: 115-125.
125. Zheng FQ, Xu Y, Yang RJ, Wu B, Tan XH, et al. (2009) Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. Acta Pharmacol Sin 30: 617-627.
126. Ma S, Qu W, Mao L, Zhu Z, Jia L, et al. (2012) Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer. Oncol Rep 27: 1443-1450.
127. Sunamura M, Oonuma M, Motoi F, Abe H, Saitoh Y, et al. (2002) Gene therapy for pancreatic cancer targeting the genomic alterations of tumor suppressor genes using replication-selective oncolytic adenovirus. Hum Cell 15: 138-150.
128. Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, et al. (2007) Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res 67: 4949-4955.
129. Stubdal H, Perin N, Lemmon M, Holman P, Bauzon M, et al. (2003) A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res 63: 6900-6908.
130. Mahoney DJ, Lefebvre C, Allan K, Brun J, Sanaei CA, et al. (2011) Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell 20: 443-456.
131. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.